Download Case Study

This case study highlights the role of EMIT Imaging and Cryo-Fluorescence Tomography (CFT) in analyzing the biodistribution of a Fibroblast-Activation Protein (FAP) imaging compound.

This research compared biodistribution in U-87 MG tumor-bearing mice by comparing a ZW800-1 fluorescent-labeled FAP compound and a 67Cu-labeled NOTA-conjugated FAP compound of otherwise analogous structure. Animals were sacrificed at 1h or 24h post-administration for gamma counting or CFT imaging, and drug uptake was determined from regions of interest in the tumor, knee joint, liver, and kidney. Biodistribution of the ZW800-1 FAP compound from CFT was compared to the accepted SPECT and gamma counting (GC) methods.

Reference: Hesterman, Novicki, White, Stokes, Cordova, Toddes, Silva, Burke, Domarkas, Wright, Archibald, Yost, Heimann, DiMagno, Hillier, Patel, Orcutt, Amor, Tully, Babich, Hoppin. EANM 2023. Preclinical characterization of novel radiolabeled and fluorescent-labeled Fibroblast-Activation Protein (FAP)-targeting ligands using gamma counting, SPECT imaging, and Cryo-Fluorescence Tomography (CFT).